Cargando…

A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder

BACKGROUND: Since about one-third of patients with major depressive disorder (MDD) do not respond adequately to available antidepressants, there is a need for treatments based on novel mechanisms of action. Neuropeptide Y (NPY), a normal brain constituent, is reduced in cerebrospinal fluid of patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathé, Aleksander A, Michaneck, Miranda, Berg, Elisabeth, Charney, Dennis S, Murrough, James W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Regular Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770516/ https://www.ncbi.nlm.nih.gov/pubmed/33009815 http://dx.doi.org/10.1093/ijnp/pyaa054

Ejemplares similares

A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder
por: Sayed, Sehrish, et al.
Publicado: (2017)

Neuropeptide y and neuropeptide s in major depressive disorder and post-traumatic stress disorder: Preclinical andclinical studies
por: Mathe, A.
Publicado: (2021)

Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson’s Disease with Comorbid Depression versus Patients with Major Depressive Disorder
por: Svenningsson, Per, et al.
Publicado: (2017)

Cerebrospinal Fluid Neuropeptide Y Levels in Major Depression and Reported Childhood Trauma
por: Soleimani, Laili, et al.
Publicado: (2014)

Neuropeptide Y in Alcohol Addiction and Affective Disorders
por: Thorsell, Annika, et al.
Publicado: (2017)

Neural correlates of rumination in major depressive disorder: A brain network analysis
por: Jacob, Yael, et al.
Publicado: (2019)

Neuropeptide Y (NPY) intranasal delivery alleviates Machado–Joseph disease
por: Duarte-Neves, Joana, et al.
Publicado: (2021)

Neuropeptides as the Shared Genetic Crosstalks Linking Periodontitis and Major Depression Disorder
por: Sun, Changsheng, et al.
Publicado: (2021)

Intranasal Neuropeptide Y as a Potential Therapeutic for Depressive Behavior in the Rodent Single Prolonged Stress Model in Females
por: Nahvi, Roxanna J., et al.
Publicado: (2021)

Amygdala substructure volumes in Major Depressive Disorder
por: Roddy, Darren, et al.
Publicado: (2021)

Non-REM sleep in major depressive disorder
por: Bovy, Leonore, et al.
Publicado: (2022)

Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours
por: Bjellerup, P, et al.
Publicado: (2000)

Intranasal Neuropeptide Y Blunts Lipopolysaccharide-Evoked Sickness Behavior but Not the Immune Response in Mice
por: Zenz, Geraldine, et al.
Publicado: (2019)

Age-dependent brain morphometry in Major Depressive disorder
por: Myoraku, Alison, et al.
Publicado: (2021)

The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
por: Dijkstra, Francis M, et al.
Publicado: (2022)

Resting state brain dynamics: Associations with childhood sexual abuse and major depressive disorder
por: Belleau, Emily L., et al.
Publicado: (2022)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
por: Carter, Maximilian, et al.
Publicado: (2022)

Heart rate variability (HRV) in adolescent females with anxiety disorders and major depressive disorder
por: Henje Blom, E, et al.
Publicado: (2010)

Self-other referential neural processing in social anxiety disorder and major depressive disorder
por: Finlayson-Short, Laura, et al.
Publicado: (2021)

Randomized, double‐blind, placebo‐controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder
por: Inoue, Takeshi, et al.
Publicado: (2019)

The relationship between depressive symptoms, general psychopathology, and well‐being in patients with major depressive disorder
por: Weijers, Annelies, et al.
Publicado: (2020)

The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials
por: McIntyre, RS, et al.
Publicado: (2016)

A Neuropeptide Y Variant (rs16139) Associated with Major Depressive Disorder in Replicate Samples from Chinese Han Population
por: Wang, Yongjun, et al.
Publicado: (2013)

Blame-rebalance fMRI neurofeedback in major depressive disorder: A randomised proof-of-concept trial
por: Zahn, Roland, et al.
Publicado: (2019)

Predictors of Electroconvulsive Therapy Outcome in Major Depressive Disorder
por: Su, Liang, et al.
Publicado: (2022)

Intranasal neuropeptide Y is most effective in some aspects of acute stress compared to melatonin, oxytocin and orexin
por: Zubkov, Eugene, et al.
Publicado: (2022)

Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Huang, I-Chen, et al.
Publicado: (2022)

Reduced fractional anisotropy in patients with major depressive disorder and associations with vascular stiffness
por: Hermesdorf, Marco, et al.
Publicado: (2017)

Accuracy of automated classification of major depressive disorder as a function of symptom severity
por: Ramasubbu, Rajamannar, et al.
Publicado: (2016)

Emotion regulation in emerging adults with major depressive disorder and frequent cannabis use
por: Nichols, Emily S., et al.
Publicado: (2021)

Internal reliability of blame-related functional MRI measures in major depressive disorder
por: Fennema, Diede, et al.
Publicado: (2021)

Targeting the neuropeptide Y system in stress-related psychiatric disorders
por: Enman, Nicole M., et al.
Publicado: (2014)

Correction: A Neuropeptide Y Variant (rs16139) Associated with Major Depressive Disorder in Replicate Samples from Chinese Han Population
por: Wang, Yongjun, et al.
Publicado: (2013)

Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder
por: Maoz, H.
Publicado: (2023)

The volumetric and shape changes of the putamen and thalamus in first episode, untreated major depressive disorder
por: Lu, Yi, et al.
Publicado: (2016)

Low-rank network signatures in the triple network separate schizophrenia and major depressive disorder
por: Han, Wei, et al.
Publicado: (2019)

Gender-specific structural abnormalities in major depressive disorder revealed by fixel-based analysis
por: Lyon, Matt, et al.
Publicado: (2019)

Frontopolar cortex activation associated with pessimistic future-thinking in adults with major depressive disorder
por: Katayama, Nariko, et al.
Publicado: (2019)

Anhedonia correlates with functional connectivity of the nucleus accumbens subregions in patients with major depressive disorder
por: Liu, Rui, et al.
Publicado: (2021)

Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine
por: Benoit, James R.A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_938oh2h6r6vscdq8h6eru1cuhu